Tags

Type your tag names separated by a space and hit enter

The effect of pravastatin and atorvastatin on coenzyme Q10.
Am Heart J. 2001 Aug; 142(2):E2.AH

Abstract

BACKGROUND

Coenzyme Q10 (CoQ10) is an antioxidant and plays an important role in the synthesis of adenosine triphosphate. Studies suggest that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors reduce CoQ10 levels; however, no studies have directly compared HMG-CoA reductase inhibitors in a randomized crossover fashion.

METHODS

Twelve healthy volunteers received either 20 mg pravastatin (P) or 10 mg atorvastatin (A) for 4 weeks in a randomized crossover fashion. There was a 4- to 8-week washout period between the 2 phases. CoQ10 levels and a lipid profile were obtained.

RESULTS

There was no difference in CoQ10 levels from baseline to post-drug therapy for either P or A (0.61 +/- 0.14 vs 0.62 +/- 0.2 microg/mL and 0.65 +/- 0.22 vs 0.6 +/- 0.12 microg/mL, respectively; P >.05). There was a significant difference in low-density lipoprotein (LDL) levels from baseline to post-drug therapy for both P and A (97 +/- 21 vs 66 +/- 19 mg/dL and 102 +/- 21 vs 52 +/- 14 mg/dL, respectively; P <.01). There was no significant correlation between LDL and CoQ10.

CONCLUSIONS

P and A did not decrease CoQ10 despite a significant decrease in LDL levels. These findings suggest that HMG-CoA reductase inhibitors do not significantly decrease the synthesis of circulating CoQ10 in healthy subjects. Routine supplementation of CoQ10 may not be necessary when HMG-CoA reductase inhibitor therapy is administered.

Authors+Show Affiliations

College of Pharmacy, the General Clinical Research Center, the Division of Cardiology, Department of Medicine, and the University of Michigan Health Systems, University of Michigan, Ann Arbor, MI 48109-1065, USA. bbleske@umich.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

11479481

Citation

Bleske, B E., et al. "The Effect of Pravastatin and Atorvastatin On Coenzyme Q10." American Heart Journal, vol. 142, no. 2, 2001, pp. E2.
Bleske BE, Willis RA, Anthony M, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J. 2001;142(2):E2.
Bleske, B. E., Willis, R. A., Anthony, M., Casselberry, N., Datwani, M., Uhley, V. E., Secontine, S. G., & Shea, M. J. (2001). The effect of pravastatin and atorvastatin on coenzyme Q10. American Heart Journal, 142(2), E2.
Bleske BE, et al. The Effect of Pravastatin and Atorvastatin On Coenzyme Q10. Am Heart J. 2001;142(2):E2. PubMed PMID: 11479481.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of pravastatin and atorvastatin on coenzyme Q10. AU - Bleske,B E, AU - Willis,R A, AU - Anthony,M, AU - Casselberry,N, AU - Datwani,M, AU - Uhley,V E, AU - Secontine,S G, AU - Shea,M J, PY - 2001/8/2/pubmed PY - 2001/8/31/medline PY - 2001/8/2/entrez SP - E2 EP - E2 JF - American heart journal JO - Am Heart J VL - 142 IS - 2 N2 - BACKGROUND: Coenzyme Q10 (CoQ10) is an antioxidant and plays an important role in the synthesis of adenosine triphosphate. Studies suggest that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors reduce CoQ10 levels; however, no studies have directly compared HMG-CoA reductase inhibitors in a randomized crossover fashion. METHODS: Twelve healthy volunteers received either 20 mg pravastatin (P) or 10 mg atorvastatin (A) for 4 weeks in a randomized crossover fashion. There was a 4- to 8-week washout period between the 2 phases. CoQ10 levels and a lipid profile were obtained. RESULTS: There was no difference in CoQ10 levels from baseline to post-drug therapy for either P or A (0.61 +/- 0.14 vs 0.62 +/- 0.2 microg/mL and 0.65 +/- 0.22 vs 0.6 +/- 0.12 microg/mL, respectively; P >.05). There was a significant difference in low-density lipoprotein (LDL) levels from baseline to post-drug therapy for both P and A (97 +/- 21 vs 66 +/- 19 mg/dL and 102 +/- 21 vs 52 +/- 14 mg/dL, respectively; P <.01). There was no significant correlation between LDL and CoQ10. CONCLUSIONS: P and A did not decrease CoQ10 despite a significant decrease in LDL levels. These findings suggest that HMG-CoA reductase inhibitors do not significantly decrease the synthesis of circulating CoQ10 in healthy subjects. Routine supplementation of CoQ10 may not be necessary when HMG-CoA reductase inhibitor therapy is administered. SN - 0002-8703 UR - https://www.unboundmedicine.com/medline/citation/11479481/The_effect_of_pravastatin_and_atorvastatin_on_coenzyme_Q10_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-8703(01)52810-0 DB - PRIME DP - Unbound Medicine ER -